Follow TopicFollow Contributor Share Feedback
Reimagining Ethics, Risks & Compliance with Behavioral Science at Novartis

Reimagining Ethics, Risks & Compliance with Behavioral Science at Novartis

by Antoine Ferrere

Global Head of Behavioral & Data Science, Novartis

May 15, 2022


It’s fair to say that when we started our journey, in September 2019, there was no established “best practice” — some easy 5-point plans or magic-quadrant-endorsed vendors — to help us in bringing behavioural science to the task of improving and transforming how we drive and embed a more reliably ethical culture, manage behavioural risks, and ensure greater compliance. There still isn’t.

The way you start matters less than getting started.

This content is available to paid Members of Starling Insights.

If you are a Member of Starling Insights, you can sign in below to access this item. 


If you are not a member, please consider joining Starling Insights to support our work and get access to our entire platform.  Enjoy hundreds of articles and related content from past editions of the Compendium, special video and print reports, as well as Starling's observations and comments on current issues in culture & conduct risk management.

Join The Discussion

See something that doesn't look quite right?

We strive to provide high quality and accurate content at all times. With that said, we realize that sometimes links break, new information becomes available, or there is something that you feel we may have missed.

If you see something that you think we should be aware of, we would love to hear from you. Feel free to drop us a note below and leave your name and contact info if you'd like to hear back from us.

Thank you for being a key part of the Starling Insights community!